Pharma prices, margin pressure likely to ease soon: industry captains

The pharmaceutical industry is optimistic that price and margin pressure in the US market will ease in the future.

According to Ajay Piramal, President of the Piramal Group, although there has been pressure on margins, especially with the uncertainty regarding costs, some of the pressure on prices has been recovered in terms of growth. value.

“Additionally, the world wants to diversify its supply chain,” he said during a panel discussion on “Riding the value chain for the next wave of growth and driving towards a resilient future” at BioAsia here. Friday.

GV Prasad of Dr Reddy’s Laboratories Ltd, said there was definitely an increase in input costs which in the short term cannot be passed on to patients.

“But I see a downward adjustment unless something like the war in Ukraine disrupts supply chains again,” he said.

According to Pankaj Patel, President and CEO of Zydus Cadila, the pandemic has hampered industry growth as there were fewer people visiting hospitals.

“Now that the world is looking for non-China based products, Indian companies have a good opportunity to make their presence felt in the global market,” he said.

The panelists also insisted on the need for competitiveness. “We need to be competitive, qualitative and strong in terms of supply. While people will be interested in creating a China plus one strategy, they will also see cost and quality as an important issue,” said Dilip Shanghvi, CEO of Sun Pharma.

We need to change a few of India’s regulatory processes so that its response time can be significantly improved, he said, adding: “If we want to become a global player at scale, we will have to be better than the current best. ‘

Published on

February 25, 2022

About Margie Peters

Check Also

Sun Pharma Q1FY23 figures: Exceed expectations, but with room for improvement

Sun Pharma released its Q1FY23 results last Friday with an overall pace – 4.8% revenue, …